BMS309403 is orally active, reducing atherosclerosis in mice lacking apoplipoprotein E.

BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (aFABP, aP2) with a Ki of <2 nM, 250, and 350 nM for aFABP, muscle FABP (mFABP), and epidermal FABP (eFABP), respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.

FABPs ligand 6 (MF6) is an FABP5 and FABP7 inhibitor with KD values of 874 nM and 20 nM, respectively. FABPs ligand 6 can be used for multiple sclerosis research.